MetaADEDB 2.0 @ LMMD
Daptomycin
(DOAKLVKFURWEDJ-RWDRXURGSA-N)
Structure
SMILES
NCCC[C@@H]1NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](Cc2c[nH]c3c2cccc3)NC(=O)CCCCCCCCC)CC(=O)N)CC(=O)O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC1=O)CC(=O)O)C)CC(=O)O)CO)[C@@H](CC(=O)O)C)CC(=O)c1ccccc1N
Type(s)
Approved; Investigational
ATC code(s)
J01XX09
Molecular Formula:
C72H101N17O26
Molecular Weight:
1620.670
Log P:
0.8828
Hydrogen Bond Acceptor:
42
Hydrogen Bond Donor:
22
TPSA:
702.02
CAS Number(s):
103060-53-3
Synonym(s)
1.
Daptomycin
2.
Cubicin
3.
Daptomycin, 9-L beta-Aspartic Acid
4.
Deptomycin
5.
LY-146032
6.
Daptomycin, 9 L beta Aspartic Acid
7.
LY 146032
8.
LY146032
External Link(s)
MeSHD017576
PubChem Compound16134395
ChEBI600103
CHEMBLCHEMBL387675
DrugBankDB00080
KEGGcpd:C12013
dr:D01080
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1ChillsFAERS: 169US FAERS
2TremorFAERS: 78US FAERS
3Blood creatine phosphokinase increasedFAERS: 73
Canada Vigilance: 3
Canada Vigilance
US FAERS
4Eosinophilic PneumoniaFAERS: 66
Canada Vigilance: 2
Canada Vigilance
US FAERS
5RhabdomyolysisFAERS: 4316410267CTD
US FAERS
6AstheniaFAERS: 24US FAERS
7MyalgiaFAERS: 23
Canada Vigilance: 1
Canada Vigilance
US FAERS
8EosinophiliaFAERS: 22
Canada Vigilance: 1
Canada Vigilance
US FAERS
9Product use in unapproved indicationFAERS: 21US FAERS
10PneumonitisFAERS: 18US FAERS
11HypotensionFAERS: 17US FAERS
12Drug ineffectiveFAERS: 14US FAERS
13PruritusFAERS: 14
Canada Vigilance: 1
Canada Vigilance
US FAERS
14SepsisFAERS: 14US FAERS
15NauseaFAERS: 12US FAERS
16Product lot number issueFAERS: 12US FAERS
17Respiratory FailureFAERS: 12US FAERS
18Suspected transmission of an infectious agent via productFAERS: 12US FAERS
19UrticariaFAERS: 10US FAERS
20Chest discomfortFAERS: 9US FAERS
21HeadacheFAERS: 9US FAERS
22No adverse eventFAERS: 9US FAERS
23PainFAERS: 8US FAERS
24TachycardiaFAERS: 8US FAERS
25Pathogen resistanceFAERS: 7
Canada Vigilance: 1
Canada Vigilance
US FAERS
26PneumoniaFAERS: 7US FAERS
27Product quality issueFAERS: 7US FAERS
28VomitingFAERS: 7US FAERS
29Chest PainFAERS: 6US FAERS
30FatigueFAERS: 6US FAERS
31PallorFAERS: 6US FAERS
32Product use issueFAERS: 6US FAERS
33Pulmonary EosinophiliaFAERS: 617207858CTD
US FAERS
34Respiratory distressFAERS: 6US FAERS
35treatment failureFAERS: 6US FAERS
36Acute kidney injuryFAERS: 516410267
18381844
CTD
US FAERS
37Creatinine renal clearance decreasedFAERS: 5US FAERS
38Drug resistanceFAERS: 5US FAERS
39ErythemaFAERS: 5US FAERS
40Feeling ColdFAERS: 5US FAERS
41HypersensitivityFAERS: 5US FAERS
42LeukopeniaFAERS: 5US FAERS
43NeutropeniaFAERS: 5US FAERS
44OverdoseFAERS: 5US FAERS
45AngioedemaFAERS: 4US FAERS
46ArthralgiaFAERS: 4US FAERS
47Blood creatinine increasedFAERS: 4US FAERS
48HypoxiaFAERS: 4US FAERS
49InfectionFAERS: 4US FAERS
50MalaiseFAERS: 4US FAERS
51MyositisFAERS: 4US FAERS
52Poor quality drug administeredFAERS: 4US FAERS
53Therapy cessationFAERS: 4US FAERS
54Urinary tract infectionFAERS: 4US FAERS
55Acute respiratory failureFAERS: 3US FAERS
56Antimicrobial susceptibility test resistantFAERS: 3
Canada Vigilance: 1
Canada Vigilance
US FAERS
57Blood glucose increasedFAERS: 3US FAERS
58DysarthriaFAERS: 3US FAERS
59Fluid overloadFAERS: 3US FAERS
60General physical health deteriorationFAERS: 3US FAERS
61Incorrect route of drug administrationFAERS: 3US FAERS
62Lip swellingFAERS: 3US FAERS
63Maternal exposure during pregnancyFAERS: 3US FAERS
64Oropharyngeal painFAERS: 3US FAERS
65PhlebitisFAERS: 3US FAERS
66Product preparation errorFAERS: 3US FAERS
67Rash erythematousFAERS: 3US FAERS
68SwellingFAERS: 3US FAERS
69Therapy changeFAERS: 3US FAERS
70Toxicity to various agentsFAERS: 3US FAERS
71WheezingFAERS: 3US FAERS
72AgranulocytosisFAERS: 2US FAERS
73AnxietyFAERS: 2US FAERS
74Aspartate Aminotransferase IncreasedFAERS: 2US FAERS
75Atrial FibrillationFAERS: 2US FAERS
76Back PainFAERS: 2US FAERS
77Bilirubin conjugated increasedFAERS: 2US FAERS
78Blood creatine increasedFAERS: 2
Canada Vigilance: 1
Canada Vigilance
US FAERS
79Blood gases abnormalFAERS: 2US FAERS
80CholestasisFAERS: 2US FAERS
81Circumstance or information capable of leading to medication errorFAERS: 2US FAERS
82CyanosisFAERS: 2US FAERS
83Depressed Level of ConsciousnessFAERS: 2US FAERS
84DiscomfortFAERS: 2US FAERS
85DizzinessFAERS: 2US FAERS
86Drug dose omissionFAERS: 2US FAERS
87Dry skinFAERS: 2US FAERS
88Extra dose administeredFAERS: 2US FAERS
89HepatitisFAERS: 2US FAERS
90HypertransaminasaemiaFAERS: 2US FAERS
91OsteomyelitisFAERS: 218606349CTD
US FAERS
92Peripheral swellingFAERS: 2US FAERS
93Poor quality product administeredFAERS: 2US FAERS
94Product complaintFAERS: 2US FAERS
95Product storage errorFAERS: 2US FAERS
96Product substitution issueFAERS: 2US FAERS
97Pulmonary toxicityFAERS: 2US FAERS
98Renal tubular necrosisFAERS: 2US FAERS
99Sinus TachycardiaFAERS: 2US FAERS
100Sinus bradycardiaFAERS: 2US FAERS
101Stevens-Johnson SyndromeFAERS: 225811541CTD
US FAERS
102Supraventricular tachycardiaFAERS: 2US FAERS
103VertigoFAERS: 2US FAERS
104Abdominal AbscessFAERS: 1US FAERS
105Abdominal discomfortFAERS: 1US FAERS
106AbscessFAERS: 12552905CTD
US FAERS
107Acute Lung InjuryFAERS: 1US FAERS
108AgitationFAERS: 1US FAERS
109Alanine Aminotransferase IncreasedFAERS: 1US FAERS
110Amylase increasedFAERS: 1US FAERS
111Apallic syndromeFAERS: 1US FAERS
112ArthritisFAERS: 1US FAERS
113Atrial FlutterFAERS: 1US FAERS
114BedriddenFAERS: 1US FAERS
115Bilirubin urine presentFAERS: 1US FAERS
116Blood bilirubin abnormalFAERS: 1US FAERS
117Blood creatine abnormalFAERS: 1US FAERS
118Blood creatine phosphokinase abnormalFAERS: 1US FAERS
119Blood creatine phosphokinase decreasedFAERS: 1US FAERS
120Blood potassium increasedFAERS: 1US FAERS
121Blood urea increasedFAERS: 1US FAERS
122BronchospasmFAERS: 1US FAERS
123Burning sensationFAERS: 1US FAERS
124CandidiasisFAERS: 1US FAERS
125Cardiac DeathFAERS: 1US FAERS
126CellulitisFAERS: 1US FAERS
127ChokingFAERS: 1US FAERS
128Clostridium difficile toxin test positiveFAERS: 1US FAERS
129Clostridium test positiveFAERS: 1US FAERS
130Dark circles under eyesFAERS: 1US FAERS
131DeafnessFAERS: 1US FAERS
132DehydrationFAERS: 1US FAERS
133Device related infectionFAERS: 1US FAERS
134Diabetes InsipidusFAERS: 1US FAERS
135Diabetes mellitus inadequate controlFAERS: 1US FAERS
136Diffuse alveolar damageFAERS: 1US FAERS
137Disease complicationFAERS: 1US FAERS
138Disease recurrenceFAERS: 1US FAERS
139Drug dispensing errorFAERS: 1US FAERS
140Drug level increasedFAERS: 1US FAERS
141Drug toxicityFAERS: 1US FAERS
142Emphysematous CholecystitisFAERS: 1US FAERS
143EndocarditisFAERS: 1US FAERS
144Eosinophil percentage increasedFAERS: 1US FAERS
145Erythema MultiformeFAERS: 1US FAERS
146Facial paralysisFAERS: 1US FAERS
147Freezing phenomenonFAERS: 1US FAERS
148Fungal test positiveFAERS: 1US FAERS
149Grip strength decreasedFAERS: 1US FAERS
150HepatotoxicityFAERS: 1US FAERS
151HyperpyrexiaFAERS: 1US FAERS
152HypersomniaFAERS: 1US FAERS
153HyporeflexiaFAERS: 1US FAERS
154Inappropriate schedule of drug administrationFAERS: 1US FAERS
155Incorrect drug administration durationFAERS: 1US FAERS
156Incorrect drug administration rateFAERS: 1US FAERS
157Incorrect product administration durationFAERS: 1US FAERS
158Inflammatory marker increasedFAERS: 1US FAERS
159Infusion site pruritusFAERS: 1US FAERS
160Infusion site reactionFAERS: 1US FAERS
161Infusion site urticariaFAERS: 1US FAERS
162Intercepted medication errorFAERS: 1US FAERS
163Intestinal PerforationFAERS: 1US FAERS
164LethargyFAERS: 1US FAERS
165LeukocytosisFAERS: 1US FAERS
166Lipase increasedFAERS: 1US FAERS
167Lung consolidationFAERS: 1US FAERS
168LymphadenopathyFAERS: 1US FAERS
169Mental status changesFAERS: 1US FAERS
170Musculoskeletal PainFAERS: 1US FAERS
171Musculoskeletal stiffnessFAERS: 1US FAERS
172NasopharyngitisFAERS: 1US FAERS
173Nephrotic SyndromeFAERS: 1US FAERS
174Night sweatsFAERS: 1US FAERS
175OliguriaFAERS: 1US FAERS
176PalpitationsFAERS: 1US FAERS
177Physical product label issueFAERS: 1US FAERS
178Pleuritic painFAERS: 1US FAERS
179PolyneuropathyFAERS: 1US FAERS
180PregnancyFAERS: 1US FAERS
181Prescribed overdoseFAERS: 1US FAERS
182Procedural complicationFAERS: 1US FAERS
183Product closure issueFAERS: 1US FAERS
184Product contamination physicalFAERS: 1US FAERS
185Product prescribing issueFAERS: 1US FAERS
186Productive CoughFAERS: 1US FAERS
187Pulmonary EmbolismFAERS: 1US FAERS
188Pulmonary FibrosisFAERS: 1US FAERS
189Pulmonary HypertensionFAERS: 1US FAERS
190Pulmonary congestionFAERS: 1US FAERS
191PurpuraFAERS: 1US FAERS
192Reaction to excipientFAERS: 1US FAERS
193Respiratory DepressionFAERS: 1US FAERS
194RetchingFAERS: 1US FAERS
195Septic ShockFAERS: 1US FAERS
196Skin UlcerFAERS: 1US FAERS
197Skin lesionFAERS: 1US FAERS
198Strangulated hernia repairFAERS: 1US FAERS
199Therapy non-responderFAERS: 1US FAERS
200ThirstFAERS: 1US FAERS
201ThrombocytopeniaFAERS: 1US FAERS
202Toxic Epidermal NecrolysisFAERS: 1US FAERS
203Troponin increasedFAERS: 1US FAERS
204Unresponsive to stimuliFAERS: 1US FAERS
205Urinary IncontinenceFAERS: 1US FAERS
206VasculitisFAERS: 1US FAERS
207White blood cell count decreasedFAERS: 1US FAERS
208Wrong technique in product usage processFAERS: 1US FAERS
209YawningFAERS: 1US FAERS
210nervous system disorderFAERS: 1US FAERS
211Bacteremia17005801
17904947
20959502
CTD
212Chemical and Drug Induced Liver Injury15743894CTD
213Corynebacterium Infections16144879CTD
214Gram-Positive Bacterial Infections17904948
20956587
21119097
CTD
215Kidney Diseases2158272CTD
216Liver diseases18381844CTD
217Meningitis, Bacterial21119097CTD
218Muscle Weakness16410267CTD
219Pyelonephritis18349306CTD
220Staphylococcal Infections

View details

CTD
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120236

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.